Cargando…

Current Control and Future Risk in Asthma Management

Despite international and national guidelines, poor asthma control remains an issue. Asthma exacerbations are costly to both the individual, and the healthcare provider. Improvements in our understanding of the therapeutic benefit of asthma therapies suggest that, in general, while long-acting bronc...

Descripción completa

Detalles Bibliográficos
Autores principales: Sims, Erika J, Price, David, Haughney, John, Ryan, Dermot, Thomas, Mike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3178819/
https://www.ncbi.nlm.nih.gov/pubmed/21966601
http://dx.doi.org/10.4168/aair.2011.3.4.217
_version_ 1782212442740228096
author Sims, Erika J
Price, David
Haughney, John
Ryan, Dermot
Thomas, Mike
author_facet Sims, Erika J
Price, David
Haughney, John
Ryan, Dermot
Thomas, Mike
author_sort Sims, Erika J
collection PubMed
description Despite international and national guidelines, poor asthma control remains an issue. Asthma exacerbations are costly to both the individual, and the healthcare provider. Improvements in our understanding of the therapeutic benefit of asthma therapies suggest that, in general, while long-acting bronchodilator therapy improves asthma symptoms, the anti-inflammatory activity of inhaled corticosteroids reduces acute asthma exacerbations. Studies have explored factors which could be predictive of exacerbations. A history of previous exacerbations, poor asthma control, poor inhaler technique, a history of lower respiratory tract infections, poor adherence to medication, the presence of allergic rhinitis, gastro-oesophageal reflux disease, psychological dysfunction, smoking and obesity have all been implicated as having a predictive role in the future risk of asthma exacerbation. Here we review the current literature and discuss this in the context of primary care management of asthma.
format Online
Article
Text
id pubmed-3178819
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease
record_format MEDLINE/PubMed
spelling pubmed-31788192011-10-01 Current Control and Future Risk in Asthma Management Sims, Erika J Price, David Haughney, John Ryan, Dermot Thomas, Mike Allergy Asthma Immunol Res Review Despite international and national guidelines, poor asthma control remains an issue. Asthma exacerbations are costly to both the individual, and the healthcare provider. Improvements in our understanding of the therapeutic benefit of asthma therapies suggest that, in general, while long-acting bronchodilator therapy improves asthma symptoms, the anti-inflammatory activity of inhaled corticosteroids reduces acute asthma exacerbations. Studies have explored factors which could be predictive of exacerbations. A history of previous exacerbations, poor asthma control, poor inhaler technique, a history of lower respiratory tract infections, poor adherence to medication, the presence of allergic rhinitis, gastro-oesophageal reflux disease, psychological dysfunction, smoking and obesity have all been implicated as having a predictive role in the future risk of asthma exacerbation. Here we review the current literature and discuss this in the context of primary care management of asthma. The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease 2011-10 2011-09-21 /pmc/articles/PMC3178819/ /pubmed/21966601 http://dx.doi.org/10.4168/aair.2011.3.4.217 Text en Copyright © 2011 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Sims, Erika J
Price, David
Haughney, John
Ryan, Dermot
Thomas, Mike
Current Control and Future Risk in Asthma Management
title Current Control and Future Risk in Asthma Management
title_full Current Control and Future Risk in Asthma Management
title_fullStr Current Control and Future Risk in Asthma Management
title_full_unstemmed Current Control and Future Risk in Asthma Management
title_short Current Control and Future Risk in Asthma Management
title_sort current control and future risk in asthma management
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3178819/
https://www.ncbi.nlm.nih.gov/pubmed/21966601
http://dx.doi.org/10.4168/aair.2011.3.4.217
work_keys_str_mv AT simserikaj currentcontrolandfutureriskinasthmamanagement
AT pricedavid currentcontrolandfutureriskinasthmamanagement
AT haughneyjohn currentcontrolandfutureriskinasthmamanagement
AT ryandermot currentcontrolandfutureriskinasthmamanagement
AT thomasmike currentcontrolandfutureriskinasthmamanagement